Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease.
← catalyst calendarNCT07268612 · readout ≤ 3,756 d
Sponsored by Emergent BioSolutions (industry) · EBS — their whole pipeline →.
Phase
—
Status
Not yet recruiting
Study type
Observational
Enrollment
250estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Nov 2035 | estimated | When the study began enrolling |
| Primary completion | Nov 2036 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2037 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Anthrax
Intervention
- Biological: CYFENDUS
Primary outcome
what the primary-completion date above is the date OFNumber of individuals who developed inhalational anthrax and/or anthrax meningitis and received CYFENDUS for post exposure prophylaxis divided by the total number reported to have received CYFENDUS for post exposure prophylaxis.
measured At least 12 months after containment of the mass exposure event
Permalink · EBS's whole pipeline · Catalyst calendar · Every registered study · What changed